News & Events

BEAM Alliance
Members
Events

Latest news from BEAM Alliance

20 October 2025 - BEAM ALLIANCE

Defining Eligibility for ‘Priority Antimicrobials’: A Critical Step for Effective PULL Incentives

The General Pharmaceutical Legislation (GPL) should provide broad guidelines for eligibility, leaving the EMA to refine the details. The GPL…

20 October 2025 - BEAM ALLIANCE

Transferable Priority Review Vouchers (TPRVs): Lessons from the US, Implications for EU

If a choice must be made, TEEV offer a clearer, more reliable incentive for SMEs, making them a more appealing…

20 October 2025 - BEAM ALLIANCE

The Future of the TEE Voucher in EU Pharmaceutical Legislation

The TEE Voucher is widely supported by SMEs, industry, and investors. Though not perfect, its predictability makes it attractive to…

20 October 2025 - BEAM ALLIANCE

How Can a Subscription Model Help Incentivizing Antimicrobial Innovation in the EU?

An EU-funded revenue guarantee (ensuring predictability and reducing reliance on voluntary participation) could be highly effective, provided the incentives are…

20 October 2025 - BEAM ALLIANCE

The Milestone Prize aimed to Support AMR Innovation Requires Careful Analysis

As things stand, we believe that the milestone prize requires further investigation in order to validate its operational feasibility and…

30 September 2025 - BEAM ALLIANCE

A Position Paper on Preventive Therapies in the Fight Against AMR

The BEAM Alliance has released a new position paper, “Prevent Before You Treat: Accelerating Access to Preventive Therapies in the…

No results

1 / 10

Latest news of BEAM Members

25 September 2025 - Basilea Pharmaceutica International

Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam

The funding helps us to further advance our newly in-licensed novel antibiotic ceftibuten-ledaborbactam, which we believe holds a strong promise…

16 September 2025 - Basilea Pharmaceutica International

Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

This third tranche of funding within the BARDA OTA will support our two ongoing phase 3 studies with fosmanogepix in…

27 August 2025 - BioVersys

BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis

Alpibectir, a small molecule acting through a novel mode of action, represents a totally new concept of overcoming resistance by…

25 August 2025 - AdjuTec Pharma

AdjuTec Pharma will lead a Eurostars Project of €2.2mill

The company’s lead product APC301 has shown excellent in vitro and in vivo efficacy towards several multidrug resistant bacteria and…

19 August 2025 - AUROBAC THERAPEUTICS

AUROBAC Starts Clinical Development of its First-in-Class Septic Shock Drug ATX101

ATX101 is a first-in-class treatment, addressing shock, organ failure and mortality in sepsis, a life-threatening condition for which current treatments…

14 August 2025 - Basilea Pharmaceutica International

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

This agreement allows us to strengthen our late-stage clinical pipeline and supports our strategy of ensuring that we have a…

No results

1 / 67

Events

3 March 2026

10th AMR Conference

Save the date! The 10th AMR Conference will be organized as a face-to-face event on 3-4 March 2026, in Basel.…

4 February 2026

Antimicrobial Chemotherapy Conference (ACC2026)

Antimicrobial Chemotherapy Conference (ACC2026) is a free, open-access virtual conference, jointly organized with BSAC and in collaboration with ADVANCE-ID and…

3 November 2025

BIO-Europe® 2025 – 31st Annual International Partnering Conference

BIO-Europe is the largest, longest-running biopharma partnering conference in Europe. It has evolved with the biotech industry to deliver an…

28 October 2025

REVIVE Webinar: Using artificial intelligence to analyse and predict susceptibility to antimicrobials

This webinar will discuss the emerging technologies in using artificial intelligence to detect antibiotic susceptibility and evaluate their potential for…

1 October 2025

Global AMR Innovators Conference (GAMRIC)

Save the date! The Global AMR Innovators Conference (GAMRIC), formerly the ESCMID-ASM Joint Conference on Drug Development for AMR, is…

9 September 2025

REVIVE Webinar: Overcoming challenges of tuberculosis drug discovery and development

Find out more about the current landscape of drug discovery for tuberculosis, including the scientific and practical challenges that hinder…

No results

1 / 29

Legal notice | Photo credits

Connect with us

contact@beam-alliance.eu
29 Avenue Tony Garnier 69007 Lyon - France